Acetyl-leucine slows disease progression in lysosomal storage disorders by Kaya, Ecem et al.
Acetyl­leucine slows disease progression in lysosomal storage 
disorders
Article  (Published Version)
http://sro.sussex.ac.uk
Kaya, Ecem, Smith, David A, Smith, Claire, Morris, Lauren, Bremova-Ertl, Tatiana, Cortina-Borja, 
Mario, Fineran, Paul, Morten, Karl J, Poulton, Joanna, Boland, Barry, Spencer, John, Strupp, 
Michael and Platt, Frances M (2020) Acetyl-leucine slows disease progression in lysosomal 
storage disorders. Brain Communications. pp. 1-52. ISSN 2632-1297 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/93880/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
 Acetyl-leucine slows disease progression in lysosomal storage disorders 
Short title: Acetyl-leucine for lysosomal diseases
Ecem Kaya1, David A Smith1, Claire Smith1, Lauren Morris1, 
Tatiana Bremova-Ertl2,6, Mario Cortina-Borja3, Paul Fineran1, Karl J Morten4, Joanna 
Poulton4, Barry Boland5, John Spencer6, Michael Strupp7 and Frances M Platt*1
1 Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK
2 Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, 
Switzerland
3 Population, Policy and Practice Research and Teaching Department, Great Ormond Street 
Institute of Child Health, University College London
4 Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, 
UK
5 Dept. of Pharmacology and Therapeutics, Western Gateway Building, College of Medicine 
and Health, University College Cork, Ireland
6 Department of Chemistry, School of Life Sciences, University of Sussex,
Brighton, UK
7 Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig 
Maximilians University, Munich, Germany
* Corresponding Author: Frances M Platt 
Email: Frances.platt@pharm.ox.ac.uk
Address: Department of Pharmacology,
University of Oxford,
Mansfield Road,
Oxford OX1 3QT, UK
Tel: 01865 271858
Fax: 01865 271853
 
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article/doi/10.1093/braincom
m
s/fcaa148/5906021 by guest on 22 Septem
ber 2020
Abstract  
Acetyl-DL-leucine is a derivative of the branched chain amino acid leucine. In observational 
clinical studies acetyl-DL-leucine improved symptoms of ataxia, in particular in patients with 
the lysosomal storage disorder, Niemann-Pick disease type C1. Here, we investigated acetyl-
DL-leucine and its enantiomers acetyl-L-leucine and acetyl-D-leucine in symptomatic Npc1-/- 
mice and observed improvement in ataxia with both individual enantiomers and acetyl-DL-
leucine. When acetyl-DL-leucine and acetyl-L-leucine were administered pre-
symptomatically to Npc1-/- mice, both treatments delayed disease progression and extended 
life span, whereas acetyl-D-leucine did not. These data are consistent with acetyl-L-leucine 
being the neuroprotective enantiomer. Altered glucose and antioxidant metabolism were 
implicated as one of the potential mechanisms of action of the L enantiomer in Npc1-/- mice. 
When the standard of care drug miglustat and acetyl-DL-leucine were used in combination 
significant synergy resulted. In agreement with these pre-clinical data, when Niemann-Pick 
disease type C1 patients were evaluated after 12 months of acetyl-DL-leucine treatment, rates 
of disease progression were slowed, with stabilisation or improvement in multiple 
neurological domains. A beneficial effect of acetyl-DL-leucine on gait was also observed in 
this study in a mouse model of GM2 gangliosidosis (Sandhoff disease) and in Tay-Sachs and 
Sandhoff disease patients in individual cases of off-label-use. Taken together, we have 
identified an unanticipated neuroprotective effect of acetyl-L-leucine and underlying 
mechanisms of action in lysosomal storage diseases, supporting its further evaluation in 
clinical trials in lysosomal disorders.
Keywords
Lysosomal storage diseases, Niemann-Pick disease type C, GM2 gangliosidosis, acetyl-
leucine, miglustat. 
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Abbreviations 
ADL Acetyl-D-Leucine
ADLL Acetyl-DL-Leucine
ADP Adenosine Diphosphate
ALL Acetyl-L-Leucine
ASIS Annual Severity Increment Score
BCAA Branched chain amino acid
BCKDHA Branched Chain Keto Acid Dehydrogenase Subunit A
CA Cerebellar Ataxia
CHO Chinese Hamster Ovary
CI-CS Clinical Impression of Change in Severity
GDH Glutamate Dehydrogenase
GSL Glycosphingolipid
LDH Lactate Dehydrogenase
LSD Lysosomal Storage Diseases
mTOR Mammalian Target of Rapamycin
NAD Nicotinamide adenine dinucleotide
NADH Nicotinamide adenine dinucleotide (reduced form)
NPC1 Niemann-Pick Disease Type C 1
MOA Mechanism of action
MoCA Montreal Cognitive Assessment
PDH Pyruvate Dehydrogenase
PDK Pyruvate Dehydrogenase Kinase
PDP Pyruvate Dehydrogenase Phosphatase
PGC-1alpha Peroxisome Proliferator-activated Receptor-gamma Coactivator 1-alpha
ROS Reactive Oxygen Species
SOD Superoxide Dismutase
SARA Scale for Assessment and Rating of Ataxia
8MWT 8-Minute-Walking-Test
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Introduction 
Acetyl-DL-leucine (ADLL) is a racemic (1:1) mixture of enantiomers and a derivative of the 
branched chain amino acid (BCAA) leucine. It has been used as a medication (Tanganil™) 
for the treatment of acute vertigo in France and former French colonies since 1957; it is 
orally available and has a good safety profile according to the Periodic Updated Safety 
Reports from Pierre-Fabre, France. Although its mechanism of action is not fully known, 
studies in a guinea pig model of acute vertigo showed that ADLL can restore membrane 
potential and excitability of abnormally polarised neurons of the medial vestibular nucleus 
(Vibert and Vidal, 2001). 
Due to the phylogenetic similarities and close interactions between vestibular and 
deep cerebellar neurons (Highstein and Holstein, 2005), and an activation of cerebellar 
neurons is an essential part of central vestibular compensation, the effects of ADLL were 
evaluated in patients with cerebellar ataxias (CA) who have impaired function of cerebellar 
neurons. ADLL was shown to be beneficial in patients with CA (Strupp et al., 2013; 
Schniepp et al., 2016). Since CA in one of the leading clinical symptoms of some lysosomal 
storage disorder (LSD) such as Niemann-Pick disease type C 1 (NPC1) and the GM2 
gangliosidoses (Tay-Sachs and Sandhoff disease), the symptomatic effects of ADLL were 
examined in 12 patients with NPC1 who were treated with the oral formulation of ADLL for 
a month (5 g/d). ADLL therapy in NPC1 patients led to significant improvements in CA as 
well as in cognition and behaviour, suggestive of potential functional benefits beyond the 
cerebellum (Bremova et al., 2015). Our findings of in vitro benefit of ADLL in Tangier 
disease fibroblasts (Colaco et al., 2019), and in vivo slowing disease progression in Sandhoff 
disease mice (Kaya et al., 2020) suggest ADLL may have the potential for therapeutic use in 
a broader range of diseases.
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In all of these studies, ADLL was administered to patients as a racemic mixture of 
acetyl-D-leucine (ADL) and acetyl-L-leucine (ALL) enantiomers. Pre-clinical studies 
implicated ALL as the active isomer responsible for postural compensation after unilateral 
vestibular damage in an animal model (Günther et al., 2015; Tighilet et al., 2015), and three 
clinical trials are ongoing with acetyl-L-leucine: NPC, GM2 gangliosidosis and ataxia 
telangiectasia (clinicaltrials.gov NCT03759639, NCT03759665, NCT03759678). CNS 
exposure of the administered compounds is equivalent within the limitations of the methods 
used, but L is metabolized rapidly whereas D is inert (Churchill et al., 2020). However, it 
remains to be determined if this proposed mechanism of action is relevant to the effects of 
ADLL and individual enantiomers in NPC.  
In the current study, we have therefore investigated the efficacy of ADLL and its 
distinct enantiomer components in a mouse model of NPC1 (Npc1-/-). We found that ADLL 
and its enantiomers significantly improved ataxia in Npc1-/- mice, in agreement with clinical 
observations with ADLL (Bremova et al., 2015). It is important to note, when administered 
pre-symptomatically ADLL (50% ALL: 50% ADL) and ALL, but not ADL, slowed the rate 
of disease progression, were neuroprotective, and significantly extended lifespan. Therefore, 
pre-clinical studies implicate ALL as the active enantiomer of ADLL responsible for the 
neuroprotective effects of the treatment.
When miglustat, the currently approved therapy for NPC1 (Patterson et al., 2007), 
was combined with ADLL in Npc1-/- mice, significant synergistic benefit resulted, including 
further extension of life span. In a cohort of NPC1 patients, the significant neuroprotective 
effects of ADLL identified in Npc1-/- mice were also observed in a 12-18-month extension 
phase of an ongoing observational study (Cortina-Borja et al., 2018). When the mechanism of 
action of ADLL and its enantiomers were investigated in the cerebellum of treated Npc1-/- 
mice, modulation of pathways involved in glucose metabolism were identified as potentially 
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mediating the beneficial effects of the L-enantiomer. Finally, in individual-cases of off-label-
use ADLL improved function in three GM2 gangliosidosis patients (Tay-Sachs and Sandhoff 
disease) and gait improvements were also demonstrated in a mouse model of Sandhoff 
disease. These findings demonstrate the distinct benefits of acetyl leucine treatments in LSDs 
and show promise for clinical applications.
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Materials and Methods
Animals and treatments. BALBc/NPC1nih (Pentchev et al., 1980) and Sandhoff (Hexb-/-) 
mice (Sango et al., 1995) were bred as heterozygotes to generate homozygous null (Npc1-/-) 
and mutant (Hexb-/-) mice, along with  their respective wild-type controls (Npc1+/+, Hexb+/+). 
Mice were housed under non-sterile conditions, with food and water available ad libitum. 
Since the phenotypic development affects both genders similarly upon Npc1 abrogation 
(Morris et al., 1982), all experiments were conducted on female mice to facilitate group 
housing from different litters using protocols approved by the UK Home Office Animal 
Scientific Procedures Act, 1986. All animal works was conducted under the UK Home Office 
licensing authority and the Project licence number is P8088558D. Mice were randomly 
assigned to treatment groups and the drugs coded and the staff blinded to treatment when 
performing behavioural analysis. 
Chinese hamster ovary cells. Wild-type and NPC1 deficient CHO cells were used for in 
vitro experiments and have been described previously (Dahl et al., 1992; Higaki et al., 2001)
Drug treatments. Acetyl leucine analogues (ALs) and miglustat treatment protocols are 
described in the supplemental experimental procedures.
Mouse behavioural analysis. The weight and activity of each mouse was recorded weekly 
until reaching the humane endpoint (defined as a loss of 1g body weight within 24h). 
CatWalk (10.5 system (Noldus)), NG Rota Rod for mice (Ugo Basile) was performed as 
described in the supplemental experimental procedures.
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Biochemical and immunohistochemical analyses
Sample preparation. Mice were saline perfused under terminal anaesthesia. Tissues for 
biochemical analysis were snap-frozen on ice-cold isopentane. For immunofluorescent 
staining, tissues were perfused with 4% PFA followed by PBS and kept in 4% PFA for 24h 
then stored in PBS containing 20% w/v sucrose. Biochemical analyses were performed on 
water-homogenised tissues (50 mg/mL) and protein content determined (BCA protein assay, 
Thermo Fisher #23227) according to the manufacturer’s instructions.
Western blot analyses. Western blot analyses were performed on mouse cerebellum as 
described in the supplemental experimental procedures.
ADP and ATP extraction. ADP and ATP were extracted with Phenol-TE from 70-150 mg 
tissues according to published methods (Chida et al., 2012). For details, see supplemental 
experimental procedures.
NAD and NADH extraction. NAD and NADH extractions were performed on 20 mg PBS 
washed fresh tissue on wet ice homogenised with a Dounce homogeniser with 400uL of 
NADH/NAD extraction buffer (Abcam NAD/NADH Assay kit-ab65348). For details, see 
supplemental experimental procedures.
Sample analysis
Sphingoid Base Measurements. Sphingoid base extraction and detection with reverse phase 
HPLC was performed as described in the supplemental experimental procedures.
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Glycosphingolipid measurements. Glycosphingolipids were extracted and measured by 
Normal Phase-HPLC according to published methods (Neville et. al., 2004). For details, see 
supplemental experimental procedures.
Cholesterol measurements. Cholesterol was measured from Folch-extracted tissues with the 
Amplex Red kit (Molecular Probes) according to the manufacturer's instructions. For details, 
refer to supplemental experimental procedures.
Flow cytometry experiments of CHO cells. Relative acidic compartment volume staining 
of live cells was with LysoTracker™ Green DND-26 (Thermo Fisher-L7526), mitochondrial 
volume was determined with MitoTracker Green (Invitrogen #M7514) and mitochondrial 
reactive oxygen species with MitoSOX Red (Invitrogen #M36008). For details, refer to 
supplemental experimental procedures.
Filipin Staining of CHO cells. Free unesterified cholesterol was visualized in CHO cells 
grown on glass coverslips using filipin labelling (from Streptomyces filipinensis (Sigma)). 
For details, refer to supplemental experimental procedures.
Immunohistochemistry. Immunohistochemistry was performed as described in the 
supplemental experimental procedures.  The antibodies used are summarised in 
Supplementary Table 1. Slides were air dried and mounted in ProLong Gold antifade 
(Invitrogen, #P36930). 
Western Blotting. Western blotting was performed as described in supplemental 
experimental procedures. The antibodies used are summarised in Supplementary Table 1.
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Image Acquisition and Quantification. Imaging of brain sections and CHO cells was 
performed with a Leica-SP8 confocal microscope. Western blot data acquisition was 
conducted with LiCOR Odyssey Infrared imaging system (Model No. 9120) and Universal 
hood II (Bio-Rad, California, USA). Mean fluorescence values, cerebellum diameters and 
areas, and cell quantifications were calculated with Fiji Version 1.51g software (Image J) 
(http://fiji.sc/Fiji) (W. Rasband, NIH, USA). See supplemental experimental procedures 
for analysis of cerebellar sections.
ADP/ATP measurements. Measurements of ADP/ATP were made using a kit from Sigma 
Aldrich (Cat#: MAK135) according to the manufacturer’s instructions. The ADP/ATP ratio 
was calculated with the equation: (RLU-C-RLUB)/RLU-A.
NAD, NADH measurements. NAD, NADH and total NAD (NADt) (NAD+NADH=NADt) 
were measured with the NAD/NADH assay kit (Abcam-ab65348). For details, refer to 
supplemental experimental procedures.
Clinical Studies
Demographics and statistical analysis of individual-cases of off-label-use of adult NPC1 
patients treated with ADLL is described in the supplemental experimental procedures.
Individual-cases of off-label-use in GM2 gangliosidosis patients are described in the 
supplemental experimental procedures.
Blinded Video-Rating is described in the supplemental experimental procedures.
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All patients gave their informed consent according to the Declaration of Helsinki prior to the 
compassionate use study. 
Statistical analysis and Power calculations
To calculate the number of mice needed for the experimental groups in this study we used 
G*Power software (http://www.gpower.hhu.de). The power was set as 0.8 and the 
significance level, α, as 0.05.  The mean lifespan of the NPC1 mouse model in our facility is 
87 days with a standard deviation of 3 days. NPC1 is a disease with no curative treatment and 
many experimental disease-modifying drugs have reported a 10-30% increase in lifespan. 
Therefore, we based our power calculation on a 10-30% effect size and a sample size of min 
5 and max 8 animals per group was determined. For statistical analysis see supplemental 
experimental procedures. 
Data availability
Data will be made available upon reasonable request.
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Results
ADLL, ALL and ADL administered during the symptomatic phase of disease 
improves ataxia in Npc1-/- mice.
Npc1-/- mice have a 10-12-week life span, with onset of symptoms (gait abnormalities, tremor 
and weight loss) beginning at 6-7 weeks of age (Williams et al., 2014). ADLL, ALL and 
ADL were administered to Npc1-/- mice in their diet (0.1 g/kg/day), with a dose identical to 
that used in observational clinical studies (Bremova et al., 2015). Untreated 9-week-old 
Npc1-/- mice exhibit statistically significant ataxia that presents as a pronounced sigmoidal 
gait, relative to wild-type mice (p<0.0001) (Supplementary Figure 1), whereas 9-week-old 
Npc1-/- mice treated with ADLL, ALL or ADL from 8-weeks of age (1 week of treatment) all 
displayed significantly reduced ataxia as determined by measuring lateral displacement from 
a straight trajectory in an automated gait analysis system (Supplementary Figure 1) (Figure 
1a and b) (p<0.0001, all treatments). These results indicate that the acute anti-ataxic effect of 
acetyl-leucine is stereoisomer-independent in Npc1-/- mice.
Pre-symptomatic treatment with ADLL, ALL and ADL improves ataxia in Npc1-/-
mice.
We investigated whether any additional benefit was conferred by AL analogues if treatment 
commenced before symptom onset. Npc1-/- mice were therefore treated pre-symptomatically 
from weaning (3 weeks of age) and assessed at 9 weeks of age (6 weeks of treatment). 
Similar to the acute treatment response, all three AL analogues tested significantly reduced 
ataxia (Figure 1a and c) (p< 0.0001 for all treatments) with the magnitude comparable to the 
effects observed with one week of treatment (Figure 1a and Supplementary Figure 1). 
https://mc.manuscriptcentral.com/braincom
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article/doi/10.1093/braincom
m
s/fcaa148/5906021 by guest on 22 Septem
ber 2020
Pre-symptomatic treatment with ADLL and ALL, but not ADL, improves gait 
abnormalities, motor function and modestly extends survival in Npc1-/-mice.
Npc1-/- mice develop motor dysfunction (measured by Rotarod) and paw placement 
abnormalities when ambulatory (measured with CatWalk). We therefore treated Npc1-/- mice 
pre-symptomatically from weaning (3 weeks of age) and assessed the mice at 8 weeks of age. 
Untreated Npc1-/- mice had a significantly improved hind paw duty cycle (Figure 1d, p= 
0.0031) and an improved hind paw stand mean (p= 0.0026) relative to wild-type mice 
(Kirkegaard et al., 2016) (Figure 1e).  Pre-symptomatic ADLL and ALL treatment of Npc1-/- 
mice resulted in a functional improvement in duty cycle of hind paws (ADLL: p= 0.0005, 
ALL: p< 0.0001) (Figure 1d) and hind paw stand mean (ADLL: p= 0.0179, ALL: p= 0.0014) 
relative to untreated Npc1-/- mice (Figure 1e). Rotarod performance was significantly 
impaired in untreated Npc1-/- mice relative to wild-type littermates (p< 0.0001) (Figure 1f). 
Treatment with ADLL (p= 0.0088) and ALL (p= 0.0070) resulted in a significant 
improvement in Rotarod performance by Npc1-/- mice (Figure 1f). ADL treatment had no 
significant benefit on Npc1-/- mouse motor function, as assessed using Catwalk (hind paw 
duty cycle p= 0.2124, hind paw stand mean p= 0.9547) or Rotarod (p= 0.2218) (Figure 1d-f). 
Relative to untreated Npc1-/- mice, the life span of animals treated from weaning was 
modestly but significantly increased by 8 days (9.1%) with ALL treatment (p= 0.0334), 4 
days with ADLL (p= 0.0305) (4.5%) and was not changed with ADL (p= 0.6908) (Figure 
1g), therefore displaying L-enantiomer selectivity.
ADLL, ALL and ADL improve neuropathology and reduce some lipid species in 
Npc1-/- mouse brain in a stereo-selective manner.
Since NPC1 disease is characterized by the accumulation of sphingoid bases (sphingosine 
and sphinganine), cholesterol, sphingomyelin, free fatty acids and glycosphingolipids (GSLs) 
(Lloyd-Evans and Platt, 2010) we measured the impact of ALs administered to Npc1-/- mice 
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from 3 weeks of age on lipid storage in the brain. At 59 days of age Npc1-/- mice exhibited 
increased lipid levels relative to wild-type (Williams et al., 2014) (Figure 2a-f). In order to 
evaluate the differential impact of the AL analogues in the CNS we analyzed the cerebellum 
and the forebrain (referred to as brain in the Figure 2) separately. Total GSLs in the forebrain 
were not significantly altered by any of the AL treatments (Supplementary Figure 2a), 
whilst ALL selectively reduced GM1a (20.1%; p= 0.0018) and GM2 (19.6%; p= 0.0222) 
(Figure 2a). Interestingly, although sphingosine levels were not significantly affected, ADLL 
and ADL reduced sphinganine levels by 13.5% (p= 0.0456) and 18.2% (p= 0.0111) 
respectively (Figure 2b and c). Analysis of the cerebellum confirmed no significant 
difference in total GSLs relative to untreated Npc1-/- mice with any of the AL analogues 
tested (Supplementary Figure 2b). However, ADLL and ALL treatment significantly 
lowered levels of specific GSLs including GA2 (ADLL: 21.3%, p= 0.0102; ALL: 23.8%, p= 
0.0042), whereas a significant reduction in GA1 was only observed with ALL treatment 
(23.5%, p= 0.0254) (Figure 2d). Sphingosine levels were increased by 19%, (p= 0.0042), 
but sphinganine was significantly reduced following ADL treatment (42.3%, p= 0.0074) 
(Figure 2e and f). These results indicate differential biological targets of the two 
enantiomers. Cholesterol levels in the forebrain and in the cerebellum were not shown as total 
brain cholesterol levels are not changed in the NPC brain (Xie et al., 2000).
ADLL slows Purkinje cell loss and ALL reduces neuroinflammation in the 
cerebellum, whereas ADL has no neuroprotective effect.
Npc1-/- mice exhibit progressive neurodegeneration, with cerebellar Purkinje neuron loss 
progressing from anterior to posterior lobes, accompanied by microglial activation (Williams 
et al., 2014) (Figure 2g). Only ADLL treatment significantly increased Purkinje cell survival 
at 59 days of age relative to untreated Npc1-/- littermates: 133% more Purkinje cells were 
present in lobules I and II (p= 0.0027), and 402% more Purkinje cells in lobule III (p= 
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0.0108) (Figure 2g and h). Other treatments did not significantly improve Purkinje cell 
survival in any cerebellar lobules (Npc1-/-ALL lobule I-II p= 0.107, lobule III p= 0.157, 
lobule IV-V p= 0.533; Npc1-/-ADL lobule I-II p= 0.60, lobule III p= 0.11, lobule IV-V p= 
0.766, compared to Npc1-/- UT) (Figure 2g and h). However, it is important to note that all 
of the Npc1-/- experimental groups (untreated-treated) possessed 5 to 10 times lower numbers 
of Purkinje cells in their cerebellum compared to wild-type mice (Supplementary Figure 
2c). In addition, only ALL treatment significantly reduced (by 20%, p= 0.0177) the 
frequency of CD68-positive activated microglia (Figure 2g and i) while other treatments did 
not have a significant impact (p= 0.1353 for Npc1-/-ADLL, p= 0.0553 for Npc1-/-ADL 
compared to Npc1-/- UT). ADL did not mediate any long term, neuroprotective effects 
assessed with Purkinje cell count and CD68 staining. Lastly, we measured myelin basic 
protein levels in the cerebellum by western blotting, and saw no changes in myelin basic 
protein content with AL treatments (Supplementary Figure 2d and e). 
All AL treatments alleviate lipid storage in non-neuronal tissues and cells.
Liver GSL levels in the Npc1-/- mice were significantly reduced in Npc1-/- mice treated with 
ADLL (26.8%, p= 0.03), ADL (26.9%, p= 0.0253) and 45.5% for ALL (p= 0.0003) 
(Supplementary Figure 2f). Quantification of the major GSL species confirmed that levels 
of GM2Gc (the most abundant GSL in the mouse liver) was decreased significantly with all 
AL analogues tested (26.7% ADLL: p= 0.0002, 45% ALL: p< 0.0001, 29% ADL: p< 
0.0001), while GM3Gc levels were only reduced significantly by ALL (54.8%: p= 0.0314) 
relative to untreated Npc1-/- mice (Figure 3a). All analogues tested caused significant and 
comparable levels of reduction of sphingosine (the catabolic break down product of 
ceramide) (ADLL 29.5%, p= 0.0233; ALL 33.2%, p= 0.0148; ADL 33.6% p= 0.0103) and its 
de novo precursor sphinganine (ADLL 32.5% p= 0.0365; ALL 37.4% p= 0.0189; ADL 
38.5% p= 0.0163) (Figure 3b and c). Total free cholesterol in Npc1-/- liver was also 
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significantly decreased after treatment with ADLL, ALL or ADL (ADLL 18.2% p= 0.0346; 
ALL 23.4% p= 0.0091; ADL 16.2 % p= 0.0210) (Figure 3d). 
Reduction of lipid species in the liver with all three AL treatments led us to 
investigate whether other non-neuronal cell types were corrected by ALs. We conducted a 
series of experiments on NPC1 deficient Chinese Hamster Ovary (CHO) cells by utilizing 
lysosomal and mitochondrial probes as well as measurements of lipid storage. NPC1 protein 
deletion/mutation results in increased lysosomal volume (Te Vruchte et al., 2014), as well as 
an increase in mitochondria (measured by MitoTracker), mitochondrial superoxide increase 
(measured by MitoSOX) (Paulina Ordonez et al., 2012). CHO cells treated with 1mM ALs 
for 24 hours resulted in normalisation of MitoSOX staining with all three drugs (p< 0.0001, 
compared to NPC1 UT) (Figure 3e and Supplementary Figure 3), and a significant 
decrease in MitoTracker Green (ADLL 16.8% p= 0.0150; ALL 17.1% p= 0.0133; ADL 
15.8% p= 0.0215) (Figure 3e and Supplementary Figure 3). We found that only 1mM 
ADLL and ALL treatment reduced relative lysosomal volume after 24h (ADLL 16.9%, p= 
0.0137; ALL 16%, p= 0.0177) (Figure 3e and Supplementary Figure 3); however, this 
beneficial effect was seen with all three acetyl leucine treatments after 72h of treatment 
(ADLL 24% p= 0.0026; ALL 22.8% p= 0.0036; ADL 22.3 % p= 0.0042) (Figure 3e and 
Supplementary Figure 3). After 72 hr AL treatment, sphingosine levels were significantly 
reduced by 22% with ADLL (p= 0.0009), 29% with ALL (p< 0.0001) and 14% with ADL 
(p= 0.0149) (Figure 3f). Total GSL levels were significantly reduced with all treatments 
(26% with ADLL p= 0.0007; 25% with ALL p= 0.0010; and 22% with ADL p= 0.0024) 
(Figure 3f). Likewise, cholesterol content was significantly reduced (18% with ADLL p= 
0.0043; 13% with ALL p= 0.0263; and 14% with ADL p= 0.0212) (Figure 3f, g). 
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ADLL synergises with miglustat in Npc1-/- mice.
We treated Npc1-/- mice with ADLL in combination with the standard of care drug miglustat 
(600mg/kg/day), resulting in a statistically significant longer life span than animals on 
monotherapy (Npc1-/- miglustat vs Npc1-/- miglustat & ADLL p= 0.0016; Npc1-/- ADLL vs 
Npc1-/- miglustat & ADLL p= 0.0063; median survivals; Npc1-/- UT: 87 days, Npc1-/- ADLL: 
91 days; Npc1-/- miglustat: 117 days, Npc1-/- miglustat & ADLL: 138 days) (Figure 4a). 
Miglustat is known to cause weight loss through appetite suppression (Priestman et al., 
2008).  When ADLL was used in combination with miglustat it prevented the weight loss 
associated with miglustat treatment (Figure 4b) but not the weight loss resulting from 
progression of the disease. Combination therapy significantly increased Rotarod performance 
(8 weeks: p= 0.0007; 10,12 weeks p< 0.0001 versus untreated Npc1-/-), with combination 
therapy associated with increased benefit relative to mice receiving either miglustat (10 
weeks: p= 0.0299; 12 weeks: p= 0.0232) or ADLL monotherapy (10,12 weeks: p< 0.0001) 
(Figure 4c). Gait analysis at 10 weeks of age demonstrated that hind Duty Cycle percentages 
were significantly improved with combination therapy (p= 0.0028) whereas miglustat 
monotherapy showed no benefit (Figure 4d and e). Stand mean significantly improved in 
mice treated either with combination therapy (p= 0.0250) or miglustat monotherapy (p= 
0.0196) (Figure 4d, f). Due to limited availability of miglustat, ALL and ADL combination 
therapies were not evaluated. 
Potential targets of Leucine analogues in the cerebellum 
We investigated the potential targets that ALs could affect in the cerebellum since this brain 
region is particularly important in NPC1-related pathology. As L-Leucine is a potent 
activator of the mammalian target of rapamycin (mTOR) (Kimball et al., 1999), which 
negatively regulates autophagy (Klionsky and Emr, 2000), we investigated mTOR and its 
phosphorylation status in the cerebellum of AL treated Npc1-/- mice. Western blotting 
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indicated that levels of mTOR and its phosphorylation on serine 2448 (Yanagisawa et al., 
2017) (phosphorylated/total protein expression ratios (p/t)) were not changed by ADLL, ALL 
or ADL (Figure 5a and d). Autophagic vacuoles accumulate in NPC1 disease, consistent 
with impaired lysosomal flux (Boland et al., 2010). None of the compounds significantly 
changed the ratio of LC3-I and LC3-II (Figure 5b and d). Furthermore, none of the ALs 
changed autophagic function or flux (Figure 5b and d). In addition, we were unable to detect 
a significant change in levels of its substrate p62/SQSTM1(Pankiv et al., 2007) (Figure 5c 
and d).
Effects on energy metabolism and anti-oxidant pathways 
In order to investigate potential disruption of branched chain amino acid metabolism we 
examined mitochondrial branched chain keto acid dehydrogenase enzyme A subunit 
(BCKDHA), which functions in the final step of the pathway that yields acetyl CoA (Harris 
et al., 2005).  Phosphorylation of BCKDHA (that inactivates the enzyme) was significantly 
reduced in untreated Npc1-/- cerebellum relative to wild type (37.6%, p= 0.0254) and the ratio 
of phosphorylated enzyme (p) and total enzyme (t)-p/t was significantly increased (36.6%, 
p= 0.0269) (Figure 5e and f) in Npc1-/- cerebellum. None of the ALs tested had a significant 
impact on either total BCKDHA levels or the extent of its phosphorylation (Figure 5e and f).  
Branched chain amino acids, especially leucine, are important for glutamine/glutamate 
balance and for energy metabolism when glucose metabolism is deficient or impaired 
(Yudkoff, 1997)(Kennedy et al., 2016). However, there was no difference in mitochondrial 
enzyme glutamate dehydrogenase (GDH) protein levels between untreated Npc1-/- and 
Npc1+/+ mice or following AL treatments (Figure 5f and g). 
The ratio of nicotinamide adenine dinucleotide and its reduced form (NAD/NADH) 
regulates various metabolic pathway enzymes, such as those involved in glycolysis and the 
TCA cycle (including pyruvate dehydrogenase enzyme) (Srivastava, 2016). NAD/NADH 
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production (mostly derived from the TCA cycle) fuels the mitochondrial respiratory chain 
and therefore is of high importance in energy metabolism (Da Veiga Moreira et al., 2015). 
We therefore measured the changes in NAD/NADH content in the cerebellum and their ratio 
upon AL treatments. NAD and NADH were decreased in Npc1-/- relative to Npc1+/+ mice 
achieving statistical significance for NADH (55.1%, p= 0.0314) and the sum of NAD and 
NADH (49.2%, p= 0.0001) (Figure 6a). Although there was no change in the levels of the 
coenzymes following AL treatments, in comparison with untreated NPC1 and WT (Figure 
6a), the NAD/NADH ratio was significantly decreased with ADLL treatment (30.7%, p= 
0.0240) (Figure 6b), which might be an indication of active TCA cycle machinery and 
glycolysis. The status of energy metabolism also can be assessed by determining adenosine 
diphosphate and adenosine triphosphate ratio (ADP/ATP). ADP/ATP ratio was also increased 
with ADLL (Figure 6c) (p= 0.0101), which might indicate increased energy expenditure and 
a glycolytic state.
ADLL increases active pyruvate dehydrogenase (PDH) levels while ALL shifts glucose 
metabolism towards PDH from lactate dehydrogenase (LDH).
We then investigated the effect of AL analogues on glucose utilization that yields NAD (via 
lactate production) or NADH (via TCA cycle), by measuring levels of pyruvate 
dehydrogenase (PDH) and lactate dehydrogenase (LDH) proteins by western blotting (Figure 
6 d-h). PDH is composed of 3 subunits: E1-3, with the active site located on the alpha 
subunit of E1. Phosphorylation of the E-1 alpha subunit inactivates the PDH enzyme (Kato et 
al., 2008). Untreated Npc1-/- mice at 59 days of age showed significantly decreased levels of 
PDH-E1 alpha (40.2%, p= 0.0009), PDH-E1 beta (61.2%, p< 0.0001), PDH-E3 binding 
protein (PDH-E3bp) (42.2%, p= 0.0005) (Figure 6d and e), while phospho-PDH (inactive 
form) (41.4%, p= 0.0092), pPDH/PDH E1alpha ratio (55.5%, p= 0.0006) and LDH increased 
in the disease group (14.2%, p= 0.0335) (Figure 6d, f and g), in comparison to WT. 
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Accordingly, the glucose metabolism preference (PDHE1 alpha/LDH) favored LDH 
dependency in untreated Npc1-/- mice (74.2%, p= 0.0060) with no detectable difference in 
proliferator-activated receptor-gamma coactivator 1-alpha levels  (Figure 6 d-i). E1 alpha 
subunit protein levels in PDHC were significantly increased by ADLL (29.1%, p= 0.0146), 
ALL (43.3%, p= 0.0004) and ADL (34.17%, p= 0.0044) in the cerebellum from treated Npc1-
/- mice (Figure 6d and e), with no changes in El beta, E2 or E3bp. The protein levels of 
phosphorylated E1 alpha subunit were not significantly different following treatment 
compared to untreated Npc1-/- mice. However, the ratio of phosphorylated E1 alpha to total 
E1 alpha subunit was reduced with ADLL (33%, p= 0.0333) (Figure 6d and f). LDH levels 
were the same in untreated and treated Npc1-/- mice (Figure 6d and g). Nevertheless, the ratio 
of E1 alpha subunit to LDH was significantly shifted in favor of PDH by ALL (49.1%, p= 
0.0494) (Figure 6h).  Finally, we measured the protein levels of PGC-1 alpha (peroxisome 
proliferator-activated receptor-gamma coactivator 1-alpha), a key regulator of oxidative 
phosphorylation (Huiyun and Walter, 2006), to determine whether this metabolic activation 
and shift towards PDH dependency correlates with changes in oxidative phosphorylation. 
There was no difference in protein levels of PGC-1 alpha between WT and NPC1 cerebellum 
or associated with AL treatments (Figure 6d and i).  
ADLL decreases pyruvate dehydrogenase kinase 2 (PDK2) protein expression.
Pyruvate dehydrogenase is phosphorylated and inactivated by pyruvate dehydrogenase kinase 
(PDK), reducing flux through the Krebs cycle. In contrast, pyruvate dehydrogenase 
phosphatase (PDP) dephosphorylates and activates PDH, increasing flux through the Krebs 
cycle (Jha et al., 2012). We therefore analyzed the expression of three PDK isoforms (PDK1, 
PDK2 and PDK4) and a single isoform of PDP (PDP1) in the cerebellum (Jha et al., 2012). 
Whilst levels of PDK1 and PDK4 in the cerebellum were not significantly different between 
59-day old Npc1-/- and Npc1+/+mice, PDK2 was significantly lower (64.4% reduction 
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compared to wild type, p< 0.0001) (Figure 6j and k). Furthermore, ADLL (which decreased 
the phosphorylation of PDH to the greatest extent) decreased PDK2 to a significantly greater 
extent relative to Npc1-/- UT group (42.3%, p= 0.0022) (Figure 6j and k). PDP1 was 
unaltered in untreated Npc1-/- cerebellum and was only significantly increased by ADL 
(27.4%, p= 0.0433) (Figure 6j and k).
Differential effects of individual enantiomers on antioxidant systems: ALL decreases 
superoxide dismutase (SOD) 1 while ADL increases SOD2.
We assessed the impact of ALs on the anti-oxidative system by measuring the cytoplasmic 
superoxide dismutase 1 (SOD1) and the mitochondrial superoxide detoxifier superoxide 
dismutase 2 (SOD2). We were unable to detect any significant difference in SOD1 protein 
levels between Npc1-/- and Npc1+/+ cerebella but observed a significant reduction in SOD2 
(25% p= 0.0061) (Figure 6l and m). We found that only ALL significantly decreased SOD1 
levels in cerebellum (15.6%, p= 0.0472) and only ADL significantly elevated SOD2 levels 
when compared to untreated Npc1-/- mice (19.8%, p= 0.0214) (Figure 6l and m). 
Neuroprotective effects of ADLL in individual-cases of off-label-use in NPC1 
patients. 
Having observed unanticipated beneficial effects of ALs in Npc1-/- mice we investigated 
whether neuroprotective effects also occurred in NPC1 patients treated with ADLL enrolled 
in an observational clinical study (Cortina-Borja et al., 2018) (for demographics of patients 
see Supplementary Table 2). Total clinical severity scores (with higher values equating to 
increasing levels of disability (Yanjanin et al., 2010)) were plotted prior to initiation of 
treatment with Tanganil™ (ADLL), incorporating available retrospective data (Figure 7a). 
All 13 patients had positive slopes of disease progression before ADLL treatment (1.8 
severity units/year was the average slope). Following initiation of ADLL treatment the 
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average slope was -1.78 (3 patients had no slope, 10 had negative slopes) equating to a 
significant reduction in disease progression and improvement in the majority of patients 
(One-sided sign test p= 0.0002) (Figure 7a). The data were also computed as Annual 
Severity Increment Scores (Cortina-Borja et al., 2018) that measures the rate of disease 
progression.  A mean of -9.1% / year (p< 0.001) in ASIS scores was observed (Figure 7b). 
When the slope each patient’s pre-treatment total severity score per year was plotted, all 
patients had positive slopes, whereas post treatment slopes were either zero or negative, 
consistent with stabilisation or improvement in disease progression (Figure 7c). When the 
treated patient data were analysed by neurological subdomains (Table 1) the majority of 
patients improved or stabilised on treatment in functional and cognitive subdomains (Table 
1). 
ADLL shows benefit in other LSDs: Effects in Sandhoff mice and GM2 
gangliosidosis patients
The Sandhoff (Hexb-/-) mouse model is pre-symptomatic up to 6-8 weeks of age. 
Subsequently, they develop tremor and their motor function begins to decline (Jeyakumar et 
al., 1999). By the later stages of the disease (12-15 weeks) they are inactive and are unable to 
complete motor function tests such as bar crossing (Jeyakumar et al., 1999). Hexb-/- animals 
were treated from weaning with ADLL (0.1 mg/kg/day, the same dose used for treatment of 
Npc1-/- mice). ADLL-treated mice had improved gait parameters; including hind stand mean 
(p=0.0323) (Figure 8a), front (p= 0.0039) and hind step cycle (p= 0.0062) (Figure 8b). To 
date, ALL and ADL have not been evaluated in the Sandhoff mouse model. 
Our findings in Sandhoff mice were extended to individual-cases of off-label-use in 
three patients with a confirmed GM2 gangliosidosis diagnosis (2 Tay-Sachs and 1 Sandhoff 
disease (the latter case in press (Bremova-Ertl et al., 2020)) treated with ADLL. We found a 
mean improvement of the Scale for Assessment and Rating of Ataxia (SARA) by 20.3%, the 
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Montreal Cognitive Assessment (MoCA) by 17.8% and the 8-M-Walking-Test (8 MWT) by 
42%, as shown in Figure 8c. All patients and caregivers also reported a subjective 
improvement and have continued treatment at the same dosage. Videos of the effect of 
treatment on gait and postural instability are shown in Videos 1-2. In addition, three 
experienced movement disorder experts performed blinded analysis of the videos, and rated 
the videos based on the Clinical Impression of Severity (CI-S) (1=normal, not at all ill; 
2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the 
most extremely ill). The unbiased observation before and after ADLL treatment showed 
statistically significant improvements on overall scoring (t-test p= 0.0039) (Figure 8d and 
Table 2). ALL and ADL have not been evaluated in clinical settings, but trials with ALL are 
being conducted (NPC (NCT03759639) and GM2 gangliosidosis (NCT03759665) and 
Ataxia-Telangiectasia (NCT03759678)).
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Discussion 
In this study, we have investigated the effects of acetyl-leucine in mouse models of NPC1 
and Sandhoff disease and in patients to better understand its therapeutic potential and to gain 
insights into its mechanism of action (MOA). 
We found that ADLL, ALL and ADL significantly improved ataxia when 
symptomatic Npc1-/- mice were treated acutely for seven days; this is in agreement with 
observational studies in NPC1 patients (Bremova et al., 2015) treated with ADLL, using the 
same dosage per kg and day. The individual enantiomers provided similar benefit to the 
racemic mixture for the symptomatic treatment of ataxia. The MOA explaining how ADLL 
and the enantiomers improve symptoms remains unknown. All AL analogues tested reduced 
lipid storage in neuronal and non-neuronal tissues in Npc1-/- mice and in CHO cells null for 
NPC1 suggesting a MOA that is not confined to neuronal cells. The AL analogues were also 
observed to differentially reduce the levels of stored lipids in the liver and, to a lesser extent, 
in the brain of treated Npc1-/- mice. The mechanism that underpins this “substrate reduction” 
action of ALs currently remains unclear, but in view of the high degree of synergy when 
combined with the substrate reduction therapy drug miglustat, it may not be a major 
contributor to AL’s therapeutic effect in NPC1 disease.
Another major finding of the current study was that ADLL and ALL (but not ADL) 
slowed disease progression when treatment was initiated before symptom onset, consistent 
with a neuroprotective mechanism. Since the neuroprotective effects were only observed with 
ADLL and ALL, this implicated ALL as the active enantiomer and demonstrates that the 
symptomatic improvement in ataxia and neuroprotection are achieved through different 
MOA. ALL significantly reduced neuroinflammation, which is important as this actively 
contributes to disease progression and reducing inflammation using nonsteroidal anti-
inflammatory drugs has previously been shown to be beneficial in Npc1-/- mice (Williams et 
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al., 2014). 
The neuroprotective effect of ADLL and ALL prompted us to determine whether 
similar effects occur in NPC1 patients treated with ADLL. We took advantage of an ongoing 
observational study in which thirteen NPC1 patients have been treated with Tanganil™ 
(ADLL) continuously for approximately 1 year and found that all patients showed 
stabilisation or improvement in clinical scores which were across all neurological domains, 
not just those relating to ataxia, supporting a more global neuroprotective effect in patients, 
analogous to those observed in the Npc1-/- mouse.  
One central question arising from these studies is the nature of the underlying MOA 
and in the case of ADLL and ALL, neuroprotective benefit in NPC1. Therefore, we 
investigated aspects of cell biology and metabolism known to be sensitive to leucine. Leucine 
has been shown to activate mTOR and reduce LC3-II and p62 in NPC1 cells (Yanagisawa et 
al., 2017). However, in this study, ADLL, ALL and ADL did not significantly affect either 
mTOR or autophagy in Npc1-/- mouse cerebellum. This might be due to the presence of the 
acetyl group, as opposed to a primary amine in leucine, blocking the interaction with mTOR, 
shown in Hela cells (Nagamori et al., 2016) or that acetyl leucine analogues distribute at the 
cellular level in a manner that prevents their interaction with mTOR. Catabolism of leucine 
serves as a source of Acetyl-CoA (Harris et al., 1985) which activates mTOR and nutrient 
sensing pathways (Son et al., 2018). However, the NPC1 cerebellum has significantly 
decreased levels of acetyl-CoA (Kennedy et al., 2016). This low acetyl-CoA content in NPC1 
might therefore prevent nutrient sensing pathway activation. The complexity of mTOR 
pathways and altered metabolism more generally in NPC1 makes it likely that the effects of 
AL will likely be context specific. 
Altered glucose/energy metabolism has previously been documented in the pre-
symptomatic Npc1-/- mouse cerebellum (Kennedy et al., 2013). PDHE1 alpha was found to 
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be inactivated and there was a shift from pyruvate/PDH dependency (upon which neurons 
rely for aerobic respiration) towards lactate/lactate dehydrogenase (i.e. anaerobic respiration). 
The consequence of this would be progressive impairment of energy generation (Kennedy et 
al., 2013). In this same study, alterations in cerebellar amino acids (including leucine), and 
low acetyl CoA were also reported (Kennedy et al., 2013). Independent metabolomics studies 
on Npc1-/- mouse liver reported imbalances in amino acid levels (Ruiz-Rodado et al., 2016). 
In view of data implicating altered energy metabolism in Npc1-/- mice, we measured 
ADP/ATP and NAD/NADH ratios, as a sensitive measure of energy status (Liana Roberts 
Stein and Imai, 2012; Murphy and Hartley, 2018) and found that ADLL treatment might have 
shifted the system towards a more TCA-dependent glycolytic state, in the absence of 
significant changes to NAD-NADH coenzyme levels, (which are lower in Npc1-/- 
cerebellum), in agreement with previous findings in Npc1-/- liver (Ruiz-Rodado et al., 2016). 
We then studied whether the shift in glycolysis is towards pyruvate utilization to produce 
lactate (anaerobic pathway) or to produce acetyl CoA (aerobic pathway). We found that 
ADLL treatment significantly increasing PDHE1alpha levels, and decreased PDH enzyme 
phosphorylation (causes enzyme inactivation) in the cerebellum suggesting activation of the 
aerobic pathway. Interestingly, PDH-deficient mice also display Purkinje neuron 
degeneration and relapsing ataxia (Pliss et al., 2013), suggesting the ability of ADLL to 
protect Purkinje cells against degeneration may be via activation of PDH. However, our 
findings are based on whole brain lysate and more detailed studies on discreet cell 
populations would be informative. This effect on PDH did not reflect a change in PGC1-
alpha protein levels (indicator of oxidative phosphorylation, OXPHOS), which might be due 
to the fact that up-regulating OXPHOS requires coenzyme NADH and ADLL treatment does 
not increase NADH levels. 
Individual enantiomers had distinct effects in NPC1 cerebellum; while ALL 
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normalizes altered levels of PDH and LDH and mildly reduces SOD1 levels, ADL enhanced 
levels of the mitochondrial reactive oxygen species (ROS) scavenger SOD2 (manganese 
dependent SOD2). The biological relevance of subtle change in SOD1 level with ALL is 
unknown and functional readouts are needed to validate this result. In vivo, ADLL and ALL 
treatments were associated with a significantly greater benefit in motor function and lifespan 
relative to ADL (Figure 1). This study suggests that targeting altered cellular metabolism in 
neurodegenerative diseases may achieve greater efficacy than using antioxidant approaches. 
The metabolic changes in Npc1-/- mice in response to AL treatments are summarized in 
Figure 9.
Finally, we explored whether the benefits of AL are to extend to other LSDs. We 
observed efficacy of ADLL in a mouse model of Sandhoff disease, one of the GM2 
gangliosidoses (Platt et al., 2012), a subgroup of GSL lysosomal storage diseases that 
includes Tay-Sachs disease: we demonstrated that ADLL treated Sandhoff mice had a 
significant increase in lifespan and improvements in motor function (Kaya et al., 2020); 
however the individual isomers ALL and ADL were not assessed. We also found 
improvement in gait parameters in Hexb-/- mice upon ADLL therapy consistent with the 
observational clinical studies we conducted. In three patients with GM2 gangliosidosis with 
ataxia that were treated with ADLL in individual-cases of off-label-use gait significantly 
improved, supporting the concept that ADLL and ALL may also be efficacious in multiple 
LSDs and other neurodegenerative diseases. 
In conclusion, we have found that a well-tolerated drug, ADLL, and its enantiomer 
ALL slow disease progression and improve motor function and lipid accumulation in murine 
and cell models of NPC1. Furthermore, in observational studies in NPC1 patients, treatment 
with ADLL was associated with improvement in multiple neurological domains and a 
significant reduction in the rate of disease progression, potentially via restoration of aerobic 
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metabolism based on the mechanistic studies conducted in the Npc1-/- mouse model.  The 
striking synergy of ADLL with miglustat in Npc1-/- mice suggests that combining these two 
drugs will lead to improved short- and long-term clinical outcomes and merits clinical trials. 
It is interesting to note that 12 of the 13 NPC1 patients in the observational clinical study 
were on the standard of care miglustat, so part of their clinical improvement may be the result 
of the synergy between the two disease modifying drugs. The individual enantiomers ALL 
and ADL have not yet been tested in combination with miglustat. The finding that both a 
mouse model of Sandhoff disease and GM2 gangliosides patients, regardless of age of onset, 
also showed clinical improvement when treated with ADLL suggest that this, and related 
analogues, may have broader utility in LSDs and more common neurodegenerative diseases. 
Based on ALL being the neuroprotective enantiomer, clinical trials with ALL are currently 
being conducted (NPC (NCT03759639), GM2 gangliosidosis (NCT03759665) and Ataxia-
Telangiectasia (NCT03759678)). 
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Figure Legends  
Figure 1. Acetyl leucine analogues impact on behavioural parameters in NPC1 mice.  
For wild type untreated (Npc1+/+ UT), NPC1 untreated (Npc1-/- UT), ADLL (Npc1-/- ADLL), 
ALL (Npc1-/- ALL), ADL (Npc1-/- ADL) treatments min 5 animals, max 7 for each group. 
*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. A) Symptomatic and pre-symptomatic 
AL treatment Y coordinates displacement of each consecutive foot from a straight-line 
trajectory. (Mean ± SD, n=6) B) Late stage AL treatment SEMs of Y coordinate changes 
(Mean ± SD, n=6; One-way ANOVA C) Early stage AL treatment SEMs of Y coordinate 
changes (Mean ± SD, n=6; One-way ANOVA). D) Early stage AL treatment front and hind 
duty cycle measurements, mean ± SD, (2-way ANOVA) E) Early stage AL treatments front 
and hind stand mean measurements, min 5 animals per group, Mean ± SD, (2-way ANOVA). 
Duty Cycle and Stand mean analyses were measured by 3-recorded runs per animal and 
quantitative results were obtained with Noldus CatWalk 10.5 software system. F) Early stage 
AL treatment motor performance measurements, min 5 animals each group, Mean ± SD, 
(One-way ANOVA). Motor function performance was measured with accelerating Rotarod 
(1 rpm per minute up to 10 rpm). G) Life expectancy percentages and median survivals 
(Gehan-Breslow-Wilcoxon test) n=6.
Figure 2. Effect of Acetyl leucine analogues on biochemical and histopathology in Npc1-
/- mice at 59 days of age. For all AL treatments n= 5 animals per group, for miglustat 
(positive control) (Npc1-/- MIG) n= 2 or n= 1. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 
0.0001. A) Glycosphingolipid (GSL) profiles in brain, mean ± SD, (2-way ANOVA). B) 
Sphingosine levels in brain. Mean ± SD, (One-way ANOVA). C) Sphinganine levels in 
brain, mean ± SD, (One-way ANOVA). D) GSLs in cerebellum, mean ± SD, (2-way 
ANOVA). E) Sphingosine in cerebellum, mean ± SD, (One-way ANOVA). F) Sphinganine 
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in cerebellum, mean ± SD, (One-way ANOVA). G) Cerebellum stained with calbindin-b 
(Purkinje cells, red) or CD68 (activated microglia, yellow). Scale bar 800 um. H) Purkinje 
cell density (Purkinje cell number normalised by perimeter of each lobule) at 59 days of age 
relative to NPC1 untreated, mean ± SD, (2-way ANOVA) I) CD68 cell density (number of 
CD68 positive microglia per area) at 59 days of age, mean ± SD, (One-way ANOVA). 
Figure 3. Effect of Acetyl leucine analogues on non-neuronal tissues and cells. For all AL 
treatments n= 5 animals per group, for miglustat (positive control) (Npc1-/- MIG) n= 2 or n= 
1. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. A) GSLs in liver, mean ± SD (2-way 
ANOVA). B) Sphingosine in liver, mean ± SD, (One-way ANOVA) C) Sphinganine in liver, 
mean ± SD, (One-way ANOVA). D) Liver cholesterol mean ± SD, (One-way ANOVA). E) 
MitoSOX(red) and MitoTracker(Green) and Lysotracker(Green) changes relative to Npc1+/+ 
with 24 and 72h 1mM ALs. CHO cells were double stained with either MitoTracker Green 
and MitoSOX red, or LysoTracker Green and propidium iodide. Single and live cell 
populations and FITC and PE fluorescence were determined by analytical Flow Cytometry. 
Mean ± SD, (2-way ANOVA). F) Sphingosine, total GSL and free cholesterol levels (72h) 
relative to Npc1+/+, Mean ± SD, (2-way ANOVA). G) NPC1 CHO cells stained with filipin 
(cyan, cholesterol) and propidium iodide (magenta, nucleus). Scale bar 20 micron. 
Figure 4. Effect of ADLL in combination with miglustat. For wild type untreated (Npc1+/+ 
UT), NPC1 untreated (Npc1-/- UT), ADLL (Npc1-/- ADLL), miglustat (Npc1-/- MIG) and 
combination (Npc1-/- miglustat & ADLL) therapies min 5 animals for each group. *p< 0.05, 
**p< 0.01, ***p< 0.001, ****p< 0.0001.  A) Survival curves (percentage of life expectancy) 
and median survivals (Gehan-Breslow-Wilcoxon test).  B) Body weight curves of 
experimental groups over the course of their life, mean ± SD. C) Motor performance 
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measurements (Rotarod) at 8, 10 and 12 weeks of age, mean ± SD (2-way ANOVA). 
Animals that did not perform the task were excluded from the experiment. D) Representative 
image of footprints of miglustat and miglustat/ADLL combination therapy relative to wild 
type E) Duty cycle measurements of front and hind paws at 10 weeks of age, Mean ± SD, (2-
way ANOVA) F) Stand mean measurements at of front and hind paws 10 weeks of age, 
Mean ± SD, (2-way ANOVA). 
Figure 5. Effects of acetyl leucine analogues on expression of proteins involved in 
nutrient sensing, autophagy, BCAA catabolism, and glutamate metabolism in 
cerebellum at 59 days of age. Wild type untreated (Npc1+/+ UT), NPC1 untreated (Npc1-/- 
UT), ADLL (Npc1-/- ADLL), ALL (Npc1-/- ALL), ADL (Npc1-/- ADL) treatments, n=5 for 
each group. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. A) mTOR, Phospho-mTOR 
expression and phospho-mTOR and mTOR ratio, Mean ± SD (2-way ANOVA). B) LC3-I, 
LC3-II expression, LC3-II and LC3-I ratios, Mean ± SD (2-way ANOVA). C) p62 levels, 
Mean ± SD, (One-way ANOVA). D) Western blots images of phospho-mTOR, mTOR, LC3 
and p62 and their beta-actin loading controls. E) BCKDH-A, pPBCKDH-A, p/t BCKDH-A 
expression, mean ± SD, (2-way ANOVA). F) BCKDHA, pBCKDHA, and GDH western blot 
images with beta-actin loading controls. G) GDH expression, mean ± SD (One-way 
ANOVA). 
Figure 6. Effects of acetyl leucine analogues on expression of proteins involved in energy 
metabolism and the antioxidant system in cerebellum at 59 days of age. Wild type 
untreated (Npc1+/+ UT), NPC1 untreated (Npc1-/- UT), ADLL (Npc1-/- ADLL), ALL (Npc1-/- 
ALL), ADL (Npc1-/- ADL) treatments, n=5 for each group. *p< 0.05, **p< 0.01, ***p< 
0.001, ****p< 0.0001. A) NAD, NADH, total NAD (NADt) measurements, mean ± SD, (2-
https://mc.manuscriptcentral.com/braincom
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article/doi/10.1093/braincom
m
s/fcaa148/5906021 by guest on 22 Septem
ber 2020
way ANOVA). B) NADH/NADH ratios, mean ± SD, (One-way ANOVA). C) ADP/ATP 
ratios mean ± SD (One-way ANOVA). D) Western blot images of PDHC, pPDH, LDH, 
PGC-1alpha and beta-actin loading controls. E) PDHC protein expressions, Mean ± SD, (2-
way ANOVA). F) pPDH expressions and pPDH/PDHE1 alpha ratios, Mean ± SD, (2-way 
ANOVA). G) LDH expression, Mean ± SD, (One-way ANOVA). H) PDHE1 alpha/LDH 
ratios, Mean ± SD, (One-way ANOVA). I) PGC 1 alpha expression, mean ± SD (One-way 
ANOVA). J) PDK 1-2-4 and PDP1 expression, Mean ± SD (2-way ANOVA). K) Western 
blot images of PDKs and PDP1 along with their beta-actin loading controls. L) SOD1 and 
SOD2 expression, mean ± SD (2-way ANOVA). M) Western blot images of SOD1 and 
SOD2 along with beta-actin loading controls. 
Figure 7. Clinical data from 13 adult NPC1 patients. For demographics see materials and 
methods A) Total clinical severity scores (maximum score 50, with higher values equating to 
increasing levels of disability (Yanjanin et al., 2010)). Data were plotted prior to initiation of 
treatment with Tanganil™ (ADLL), incorporating available retrospective data B) Clinical 
data computed as Annual Severity Increment Scores (Cortina-Borja et al., 2018), (p< 0.001 in 
ASIS score) C) Slope of total severity score (severity units per year) before and after ADLL 
treatment. Each individual participant in this observational study is colour coded. 
Figure 8. Effects of Acetyl-DL-Leucine on behavioural and biochemical parameters in 
12-week-old Sandhoff disease mice and GM2 patients. Sandhoff untreated (Hexb-/- UT), 
ADLL (Hexb-/-ADLL). 6-8 animals per group. A) Front-hind stand mean measurements of 
Hexb-/- UT and Hexb-/-ADLL, Mean ± SD, *p= 0.0323, 2-way ANOVA. B) Front-hind step 
cycle measurements of Hexb-/- UT and Hexb-/-ADLL, Mean ± SD, **p< 0.0063, 2-way 
ANOVA. C) Percent improvement in clinical scores in three patients with GM2 
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gangliosidosis on baseline and after one month on medication with N-Acetyl-DL-Leucine 
(ADLL). Scale for Assessment and Rating of Ataxia (SARA) Montreal Cognitive 
Assessment (MoCA) and 8-M-Walking-Test (8 MWT) were assessed. 3rd patient was 
excluded from MoCA because the test is not approved for children. See also Videos 1-2. D) 
Unbiased Clinical Impression of Change in Severity (CI-CS) scores of GM2 patient videos. 
CI-CS Skala Clinical Impression of Change in Severity; 1=normal, not at all ill; 2=borderline 
ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most 
extremely ill patients. Paired t test, p=0.0039. For individual scoring data see Table 2. 
Figure 9. Summary table. Summary table of the effect of AL treatments on investigated 
pathologies in vivo, ex vivo and in vitro, along with the proposed mechanism of AL 
treatments in the cerebellum. Red arrows indicate the pathologies in NPC1 relative to its 
wild-type counterparts. Green arrows indicate the significant changes in response to acetyl-
leucine treatment.
Table 1. Number of patients (total cohort n=13) that improved, stabilised or deteriorated 
following ADLL treatment stratified by the neurological domains scored (NIH NCSS).
Table 2. CI-CS scoring of 3 GM2 patients by 3 blinded and unbiased experts.
Video 1
A 28-year old male patient with juvenile-onset Tay-Sachs disease, Eight-Meter Walk Test is 
shown. Note the gait instability with increased fall risk at baseline. The patient is not able to 
walk independently, constant support of either assistant, or the wall is required. After one 
month on medication with N-Acetyl-DL-Leucine (ADLL), the patient has more postural 
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stability, the gait pattern changes with increased pace rate and reduced variability and 
postural sway. 
Video 2
Eight-Meter-Walk-Test of a 32-year old female patient with adult-onset Tay-Sachs disease is 
shown prior to and after 1 month on medication with N-Acetyl-DL-Leucine (ADLL). Note 
the more stable nature of the gait pattern with decreased fall risk on medication. 
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Gait parameters
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Biochemistry
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Mitochondrial volume 0
Mitochondrial ROS 0
0
Npc    UT Npc    UT Npc   ADLL Npc    ALL Npc    ADL+/+ -/- -/- -/- -/-
Cerebellum at 59 days of age
Survival 0
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Neurological Domains Improved Stable Deteriorated
Eye movement 8 4 1
Ambulation 8 4 1
Speech 3 7 3
Swallow 10 2 1
Fine motor skills 8 3 2
Cognition 6 6 1
Memory 10 2 1
                  
Table 1 Number of patients (total cohort n=13) that improved, stabilised or deteriorated 
following ADLL treatment stratified by the neurological domains scored (NIH NCSS).
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Examiner 
Number
Patient 
1 
Baseline
Patient 
1
Treated
Patient 
2
Baseline
Patient 
2
Treated
Patient 
3
Baseline
Patient 
3
Treated
Paired t-
test
1 5 4 3 3 3 3
2 6 5 4 3 5 4
3 6 5 5 5 6 5
Mean 5.67 4.67 4 3.67 4.67 4 p=0.0039
Table 2. Blinded scoring of GM2 gangliosidosis patient videos pre and post ADLL 
treatment. 
CI-CS Skala Clinical Impression of Change in Severity 1=normal, not at all ill; 2=borderline 
ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most 
extremely ill patients
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Abbreviated Summary:
This study investigates the disease-modifying effect of acetyl-DL-leucine in two 
neurodegenerative lysosomal storage diseases with different aetiologies: Niemann-
Pick type C and GM2 gangliosidosis in both murine models and clinical studies. 
Acetyl-DL-leucine and its L enantiomer provide neuroprotection likely by altering 
metabolism – a new therapeutic approach for these diseases.
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